Jounce Therapeutics (JNCE) Reports Q2 Loss of $0.14/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jounce Therapeutics (JNCE) PT Lowered to $15 at Baird
August 9, 2018 11:11 AM EDTBaird lowered its price target on Jounce Therapeutics (NASDAQ: JNCE) to $15.00 (from $20.00) while maintaining an Outperform rating following results.
Analyst Michael Ulz said the most notable update was the addition of two combination cohorts (ipiliumamb and pembrolizumab) to the ICONIC study, while the... More
